In the high-dose group, patients treated with SIMCOR combination
therapy showed similar (non-inferior) improvements in non-HDL of 11 percent
(1000 mg/40 mg) and 17 percent (2000 mg/40 mg) compared to a 10 percent
improvement with 80 mg simvastatin therapy alone. Additionally, the
high-dose combination group demonstrated significant improvements in HDL of
15 percent (1000 mg/40 mg) and 22 percent (2000 mg/40 mg) compared to a 1
percent decrease among those receiving 80 mg simvastatin monotherapy.
Triglyceride levels among the high-dose combinations groups dropped 23
percent and 32 percent, respectively, in contrast to a 0.3 percent increase
in those randomized to 80 mg simvastatin monotherapy.
Treatment with the four different doses of Niaspan combined with
simvastatin for 24 weeks was well tolerated. There was no evidence for
increased risk of hepatotoxicity or myopathy with the combination.
Treating Beyond LDL
Treatment of high cholesterol has long centered on the use of statins,
including simvastatin, to lower LDL cholesterol, which has been the primary
target of therapy. Clinical consensus now also emphasizes the importance of
comprehensive cholesterol management, including management of HDL levels,
in impacting cardiovascular risk.
In fact, a recent post-hoc analysis of 9,770 patients from the Treating
to New Targets study, published in the New England Journal of Medicine,
concluded HDL levels were predictive of major cardiovascular events in
patients treated with statins, and also observed in patients with LDL
levels below the National Cholesterol Education Program's most aggressive
target of 70 mg/dL.
"We hope to make comprehensive cholesterol treatment more effective,
more tolerable and more convenient for patients at risk for cardiovascular
disease," said Eugene Sun, M.D., vice president of Global Clinical
Development, Abbott.
About Niaspan
Available since 1997, Niaspan is the only FDA-approved, once-daily
extended-r
'/>"/>
SOURCE Abbott Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine news :1.
New Drug Application Submitted for Investigational Antibiotic Doripenem2.
Astrazenecas Investigational Cancer Therapies Revealed at ASCO3.
Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke4.
Novel Investigational Drug May Help American Women Suffering from Breast Pain5.
Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
6.
Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries7.
Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries8.
Roche offers HIV drug expertise to poor nations9.
Magnesium sulfate offers no help in migraine treatment10.
Drug Offers Hope for Alzheimers disease11.
Drug Firm Offers to Donate Smallpox Vaccine